Literature DB >> 34415479

Mitogen-Activated Protein Kinase and Aquaglyceroporin Gene Expression in Treatment Failure Leishmania major.

Reza Somee1,2, Gilda Eslami3, Mahmood Vakili4.   

Abstract

PURPOSE: Leishmaniasis comprises various clinical forms mainly including cutaneous, muco-cutaneous, and visceral leishmaniasis; caused by Leishmania species. Antimoniate is the first-line treatment but some cases showed no response to treatment in the worldwide. In this study, mitogen-activated protein kinase (MAPK) and aquaglyceroporin 1 (AQP1) gene expressions were assessed in treatment failure clinical isolates of Leishmania major. Also, molecular and phylogenic analyses of the mentioned isolates were performed.
METHODS: Samples were obtained from the patients with suspicious CL referred to the laboratory of Diagnosis Center, Gorgan Province, Iran, from October 2016 to December 2019. Detection and identification of the parasite was performed. The genes expressions of MAPK1 and AQP1 were done using SYBR Green real-time PCR. The AQP1 gene from the isolates with treatment failure was sequenced and analyzed using BLAST and multiple alignments. The phylogenic analysis was done using MEGA7. The statistical analysis was done using SPSS 16.0 by non-parametric Mann-Whitney U test.
RESULTS: All clinical isolates were detected L. major. The mean AQP1 and MAPK1 gene expressions in treatment failure isolates were 58.71 and 6.139 fold less than the ones in treatment response isolates, respectively. Based on the AQP1 gene sequence, a nucleotide change of aspartic acid with asparagine at the site 234 was observed. Phylogenic tree analysis showed three groups with the minimum dissimilarity of 0.008 between TF isolates with the standard L. major strains.
CONCLUSION: We showed that MAPK1 and AQP1 may have critical roles in response to antimoniate in clinical isolates L. major in this study.
© 2021. Witold Stefański Institute of Parasitology, Polish Academy of Sciences.

Entities:  

Keywords:  Cutaneous; Leishmaniasis; Meglumine antimoniate; Phylogeny

Mesh:

Substances:

Year:  2021        PMID: 34415479     DOI: 10.1007/s11686-021-00463-8

Source DB:  PubMed          Journal:  Acta Parasitol        ISSN: 1230-2821            Impact factor:   1.440


  23 in total

1.  The parasiticidal effect of electricity on Leishmania major, both in vitro and in vivo.

Authors:  H Hejazi; G Eslami; A Dalimi
Journal:  Ann Trop Med Parasitol       Date:  2004-01

2.  Modulation of Leishmania major aquaglyceroporin activity by a mitogen-activated protein kinase.

Authors:  Goutam Mandal; Mansi Sharma; Martin Kruse; Claudia Sander-Juelch; Laura A Munro; Yong Wang; Jenny Veide Vilg; Markus J Tamás; Hiranmoy Bhattacharjee; Martin Wiese; Rita Mukhopadhyay
Journal:  Mol Microbiol       Date:  2012-07-26       Impact factor: 3.501

Review 3.  New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape.

Authors:  Alice Machado-Silva; Pedro Pires Goulart Guimarães; Carlos Alberto Pereira Tavares; Rubén Dario Sinisterra
Journal:  Expert Opin Ther Pat       Date:  2014-12-20       Impact factor: 6.674

Review 4.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

5.  Biochemical characterization of Leishmania major aquaglyceroporin LmAQP1: possible role in volume regulation and osmotaxis.

Authors:  Katherine Figarella; Nestor L Uzcategui; Yao Zhou; Ann LeFurgey; Marc Ouellette; Hiranmoy Bhattacharjee; Rita Mukhopadhyay
Journal:  Mol Microbiol       Date:  2007-07-19       Impact factor: 3.501

Review 6.  Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases.

Authors:  Alison Hindley; Walter Kolch
Journal:  J Cell Sci       Date:  2002-04-15       Impact factor: 5.285

7.  Leishmaniasis worldwide and global estimates of its incidence.

Authors:  Jorge Alvar; Iván D Vélez; Caryn Bern; Mercé Herrero; Philippe Desjeux; Jorge Cano; Jean Jannin; Margriet den Boer
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

8.  Molecular Analysis of Aquaglyceroporin 1 Gene in Non-Healing Clinical Isolates Obtained from Patients with Cutaneous Leishmaniasis from Central of Iran.

Authors:  Yasaman Alijani; Saeedeh Sadat Hosseini; Salman Ahmadian; Sonia Boughattas; Gilda Eslami; Shadi Naderian; Vahid Ajamein
Journal:  J Arthropod Borne Dis       Date:  2019-06-24       Impact factor: 1.198

9.  Molecular characteristic of treatment failure clinical isolates of Leishmania major.

Authors:  Gilda Eslami; Samira Hatefi; Vahid Ramezani; Masoud Tohidfar; Tatyana V Churkina; Yuriy L Orlov; Saeedeh Sadat Hosseini; Mohammad Javad Boozhmehrani; Mahmood Vakili
Journal:  PeerJ       Date:  2021-03-11       Impact factor: 2.984

10.  Relationship of Leishmania RNA Virus (LRV) and treatment failure in clinical isolates of Leishmania major.

Authors:  Mohsen Abtahi; Gilda Eslami; Serena Cavallero; Mahmood Vakili; Saeedeh Sadat Hosseini; Salman Ahmadian; Mohammad Javad Boozhmehrani; Ali Khamesipour
Journal:  BMC Res Notes       Date:  2020-03-04
View more
  1 in total

1.  The role of ATP-binding cassette transporter genes expression in treatment failure cutaneous leishmaniasis.

Authors:  Mohammad Javad Boozhmehrani; Gilda Eslami; Ali Khamesipour; Abbas Ali Jafari; Mahmood Vakili; Saeedeh Sadat Hosseini; Vahideh Askari
Journal:  AMB Express       Date:  2022-06-16       Impact factor: 4.126

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.